FY2028 EPS Estimates for argenx Lifted by Leerink Partnrs

argenx SE (NASDAQ:ARGX) – Research analysts at Leerink Partnrs lifted their FY2028 earnings per share (EPS) estimates for argenx in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of $34.69 for the year, up from their previous forecast of $34.23. The consensus estimate for argenx’s current full-year earnings is $2.78 per share. Leerink Partnrs also issued estimates for argenx’s FY2029 earnings at $41.83 EPS.

Several other research analysts have also commented on the stock. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and raised their price objective for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and raised their price target for the company from $515.00 to $650.00 in a research report on Friday, November 1st. Truist Financial reiterated a “buy” rating and issued a $700.00 price objective (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and set a $717.00 target price (up from $670.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, Baird R W lowered argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, argenx has an average rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Trading Up 3.1 %

ARGX opened at $671.74 on Thursday. The firm has a market cap of $40.81 billion, a price-to-earnings ratio of -763.34 and a beta of 0.58. The stock’s 50-day moving average price is $635.64 and its 200 day moving average price is $574.35. argenx has a 12-month low of $349.86 and a 12-month high of $678.21.

Institutional Investors Weigh In On argenx

Hedge funds have recently made changes to their positions in the business. Creative Planning grew its position in argenx by 15.5% in the 2nd quarter. Creative Planning now owns 3,528 shares of the company’s stock valued at $1,517,000 after buying an additional 474 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of argenx in the 2nd quarter worth $755,000. GAMMA Investing LLC boosted its holdings in shares of argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after acquiring an additional 56 shares in the last quarter. Perpetual Ltd acquired a new position in shares of argenx during the third quarter worth about $76,314,000. Finally, Ritholtz Wealth Management purchased a new position in argenx during the third quarter worth about $262,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.